Occam Places Colin McCracken as CEO at Evonetix
Evonetix, a next generation synthetic biology company leveraging semiconductor technology to generate long, double-stranded DNA with high-fidelity at scale, has added Colin McCracken as CEO. To date, the UK-based platform company has raised $45M led by Foresite, DCVC, Draper Esprit and Morningside.
McCracken brings over twenty years’ experience in commercial and business development roles. Prior to joining Evonetix he was SVP & Chief Commercial Officer at Fluidigm where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. He has delivered commercial success in numerous leadership positions, including Vice President & General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President & Head of European Sales at Life Technologies and National Sales Manager at Qiagen.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.